ALK and prostate carcinoma: A recent case report demonstrated a clinical response to the second-generation ALK inhibitor alectinib in a patient with de novo NEPC harboring an ALK p.F1174C activating mutation, suggesting that targeting ALK could be relevant in selected patients with prostate cancer (16).